Title

The integrase era: Roll out of dolutegravir in low- and middle-income countries

Code

THSY11

Session Type

Symposia Session

Venue

Hall 12

Date Time

Thursday 26 July, 16:30 - 18:00

Co-Chairs:

Kenly Sikwese, African Community Advisory Board (AFROCAB), Zambia
Leonard Lutegama Maboko, Tanzania Commission for Aids, United Republic of Tanzania

A number of low- and middle-income countries have moved or are poised to move to a first line ART regimen containing dolutegravir. There are advantages and disadvantages to these wholescale public health interventions. This symposium will interrogate some of the foreseen and less obvious benefits and consequences of doing so.

16:30	Introduction

16:35	ART, side effects, resistance, and long term options Daniel Kuritzkes, Harvard Medical School, United States	Slides

16:50	ART, preference, and long term adherence

17:05	ART, women, and long acting contraception Chelsea Morroni, Botswana-UPenn Partnership, Botswana	Slides

17:20	ART and the public health approach

17:35	Moderated panel discussion Martina Penazzato, World Health Organization (WHO), Switzerland Francois Venter, University of Witwatersrand, South Africa Beatriz Grinsztejn, Instituto de Pesquisa Clinica Evandro Chagas-Fiocruz, Brazil

18:00	ARV: User perspective Martha Akello, International Community of Women Living with HIV Eastern Africa, Uganda

18:10	Choice matters: Listening to women’s voices Jacque Wambui, National Network of People Living with HIV and AIDS in Kenya, Kenya	Slides